Abcellera Biologics/$ABCL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abcellera Biologics
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Ticker
$ABCL
Sector
Primary listing
Employees
596
Headquarters
Vancouver, Canada
Website
ABCL Metrics
BasicAdvanced
$1.7B
-
-$0.56
0.65
-
Price and volume
Market cap
$1.7B
Beta
0.65
52-week high
$6.52
52-week low
$1.89
Average daily volume
5.6M
Financial strength
Current ratio
11.073
Quick ratio
9.496
Long term debt to equity
13.622
Total debt to equity
14.108
Profitability
EBITDA (TTM)
-218.379
Gross margin (TTM)
-413.31%
Net profit margin (TTM)
-503.91%
Operating margin (TTM)
-750.29%
Effective tax rate (TTM)
16.66%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-10.95%
Return on equity (TTM)
-15.64%
Valuation
Price to revenue (TTM)
50.711
Price to book
1.65
Price to tangible book (TTM)
1.81
Price to free cash flow (TTM)
-11.995
Free cash flow yield (TTM)
-8.34%
Free cash flow per share (TTM)
-0.469
Growth
Revenue change (TTM)
-0.54%
Earnings per share change (TTM)
5.65%
3-year revenue growth (CAGR)
-59.83%
3-year earnings per share growth (CAGR)
-4.19%
What the Analysts think about ABCL
Analyst ratings (Buy, Hold, Sell) for Abcellera Biologics stock.
Bulls say / Bears say
Total revenue jumped to $17.1 million in Q2 2025 from $7.3 million in Q2 2024, driven by increased research fees from partner-initiated programs (Business Wire)
AbCellera initiated dosing of first participants in the Phase 1 trial of ABCL635 for vasomotor symptoms, completing its transition to a clinical-stage biotechnology company (Business Wire)
AbCellera ended Q2 2025 with approximately $753 million in available liquidity—$580 million in cash and equivalents plus $173 million in non-dilutive funding—to execute on its pipeline strategy (Business Wire)
Total revenue fell to $4.2 million in Q1 2025 from $9.95 million in Q1 2024, reflecting volatility in partnership-generated research fees (Business Wire)
Net loss widened to $45.6 million in Q1 2025 from $40.6 million in Q1 2024, increasing the loss per share to $(0.15) and underscoring a high R&D burn rate (Business Wire)
The majority of AbCellera’s revenues are research fees, making its top-line performance susceptible to the timing and scope of partner agreements and milestone recognition (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
ABCL Financial Performance
Revenues and expenses
ABCL Earnings Performance
Company profitability
ABCL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abcellera Biologics stock?
Abcellera Biologics (ABCL) has a market cap of $1.7B as of October 16, 2025.
What is the P/E ratio for Abcellera Biologics stock?
The price to earnings (P/E) ratio for Abcellera Biologics (ABCL) stock is 0 as of October 16, 2025.
Does Abcellera Biologics stock pay dividends?
No, Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders as of October 16, 2025.
When is the next Abcellera Biologics dividend payment date?
Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders.
What is the beta indicator for Abcellera Biologics?
Abcellera Biologics (ABCL) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.